3.40 USD
↗ 0.00 (0.00%)AT CLOSE (11:59 AM EDT)
Zura Bio Limited Class A Ordinary Shares
ZURANASDAQ • USD
3.43
↗ 0.03 (0.74%)
POST MARKET (AS OF 07:19 PM EDT)
Post Market
AS OF 07:19 PM EDT
3.43
↗ 0.03 (0.74%)
Market: CLOSED
Open?$3.67
High?$3.74
Low?$3.25
Prev. Close?$3.40
Volume?5.0M
Avg. Volume?834.7K
VWAP?$3.39
Rel. Volume?5.94x
Bid / Ask
Bid?$3.31 × 100
Ask?$3.55 × 100
Spread?$0.24
Midpoint?$3.43
Valuation & Ratios
Market Cap?322.6M
Shares Out?95.0M
Float?52.0M
Float %?54.8%
P/E Ratio?N/A
P/B Ratio?1.49
EPS?-$1.12
Dividend?0.00%
Ex-Dividend?N/A
Zura Bio Limited Class A Ordinary Shares (ZURA) trades at $3.41 per share. Our models show a "Strong Sell" technical signal alongside a "Neutral" fundamental rating. Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
Employees
40
Market Cap
322.6M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2023-03-21
Address
4225 EXECUTIVE SQUARE
LA JOLLA, CA 92037
Phone: 858-247-0520
LA JOLLA, CA 92037
Phone: 858-247-0520
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?50
Short Sent.?59
Piotroski F-Score?0/9Weak
Altman Z-Score?14.91Safe
Confidence?45%Low
Short InterestHigh
Short % of Float?12.00%High
Short Interest?6.2M
Days to Cover?9.2
Free Float52.0M
Avg Daily Volume675.7K
Settlement Date2026-05-15
Financial Health
Current Ratio?19.33Strong
Quick Ratio?19.33Strong
Cash Ratio?19.21Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.49CHEAP▾
Peers100
S&P87
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-1.2CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-48.9%WEAK▾
S&P3
ROA?-46.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-72752000
Enterprise Value?$97.0M
Fundamentals ratios updated end of day